<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32221402</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>27</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Investigating LGALS3BP/90&#x2009;K glycoprotein in the cerebrospinal fluid of patients with neurological diseases.</ArticleTitle><Pagination><StartPage>5649</StartPage><MedlinePgn>5649</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5649</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-62592-w</ELocationID><Abstract><AbstractText>Galectin-3 binding protein (LGALS3BP or 90&#x2009;K) is a secreted glycoprotein found in human body fluids. Deregulated levels were observed in cancer and infection and its study in neurological diseases is more recent. Here, we have investigated 90&#x2009;K from human cerebrospinal fluid (CSF) of patients with amyotrophic lateral sclerosis (ALS, n&#x2009;=&#x2009;35) and other neurological diseases (n&#x2009;=&#x2009;23). CSF was fractionated by ultrafiltration/size-exclusion chromatography (SEC) and eluted fractions were analysed by complementary techniques including immunoblotting, electron microscopy and nano-liquid chromatography-tandem mass spectrometry. A fraction of 90&#x2009;K appeared as nanoparticles of irregular shape with heterogeneous dimensions of 15-60&#x2009;nm that co-eluted with extracellular vesicles in SEC. Median levels of 90&#x2009;K quantified by ELISA were not different between ALS patients (215.8&#x2009;ng/ml) and controls (213.3&#x2009;ng/ml) in contrast with the benchmark biomarker for ALS phosphoneurofilament heavy chain (1750 and 345&#x2009;pg/ml, respectively). A multiregression model supported age is the only independent predictor of 90&#x2009;K level in both groups (p&#x2009;&lt;&#x2009;0.05). Significant correlation was found between 90&#x2009;K levels and age for the ALS group (r&#x2009;=&#x2009;0.366, p&#x2009;=&#x2009;0.031) and for all subjects (r&#x2009;=&#x2009;0.392, p&#x2009;=&#x2009;0.003). In conclusion, this study unveils the presence of 90 K-containing nanoparticles in human CSF and opens novel perspectives to further investigate 90&#x2009;K as potential aging marker.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>J&#xfa;lia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7782-6319</Identifier><AffiliationInfo><Affiliation>Laboratory of Glycobiology, Instituto de Tecnologia Qu&#xed;mica e Biol&#xf3;gica Ant&#xf3;nio Xavier, Universidade Nova de Lisboa, Avenida da Rep&#xfa;blica, 2780-157, Oeiras, Portugal. jcosta@itqb.unl.pt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pronto-Laborinho</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular-Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular-Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gromicho</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2111-4579</Identifier><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular-Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonucci</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Electron Microscopy Facility, Instituto Gulbenkian de Ci&#xea;ncia, Oeiras, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tranfield</LastName><ForeName>Erin</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1542-7459</Identifier><AffiliationInfo><Affiliation>Electron Microscopy Facility, Instituto Gulbenkian de Ci&#xea;ncia, Oeiras, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Correia</LastName><ForeName>Catarina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>UniMS - Mass Spectrometry Unit, IBET - Instituto de Biologia Experimental e Tecnologica, Oeiras, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UniMS - Mass Spectrometry Unit, ITQB - Instituto de Tecnologia Quimica e Biologica Antonio Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexandre</LastName><ForeName>Bruno M</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0002-7381-9258</Identifier><AffiliationInfo><Affiliation>UniMS - Mass Spectrometry Unit, IBET - Instituto de Biologia Experimental e Tecnologica, Oeiras, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UniMS - Mass Spectrometry Unit, ITQB - Instituto de Tecnologia Quimica e Biologica Antonio Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular-Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Neurosciences and Mental Health, Hospital de Santa Maria-CHULN, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C081856">LGALS3BP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067128" MajorTopicYN="N">Extracellular Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32221402</ArticleId><ArticleId IdType="pmc">PMC7101329</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-62592-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-62592-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Loimaranta V, Hepojoki J, Laaksoaho O, Pulliainen AT. Galectin-3-binding protein: A multitask glycoprotein with innate immunity functions in viral and bacterial infections. J. Leukoc. Biol. 2018;104:777&#x2013;786. doi: 10.1002/JLB.3VMR0118-036R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3VMR0118-036R</ArticleId><ArticleId IdType="pubmed">29882603</ArticleId></ArticleIdList></Reference><Reference><Citation>Escrevente C, et al. Sialoglycoproteins and N-glycans from secreted exosomes of ovarian carcinoma cells. PLoS One. 2013;8:e78631. doi: 10.1371/journal.pone.0078631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0078631</ArticleId><ArticleId IdType="pmc">PMC3840218</ArticleId><ArticleId IdType="pubmed">24302979</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobelli S, et al. Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. FEBS Lett. 1993;319:59&#x2013;65. doi: 10.1016/0014-5793(93)80037-u.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(93)80037-u</ArticleId><ArticleId IdType="pubmed">8454062</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J. 1998;17:1606&#x2013;1613. doi: 10.1093/emboj/17.6.1606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/17.6.1606</ArticleId><ArticleId IdType="pmc">PMC1170508</ArticleId><ArticleId IdType="pubmed">9501082</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, et al. N-Glycosylation of Extracellular Vesicles from HEK-293 and Glioma Cell Lines. Anal. Chem. 2018;90:7871&#x2013;7879. doi: 10.1021/acs.analchem.7b05455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.7b05455</ArticleId><ArticleId IdType="pubmed">29888905</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, et al. Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 2018;20:332&#x2013;343. doi: 10.1038/s41556-018-0040-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-018-0040-4</ArticleId><ArticleId IdType="pmc">PMC5931706</ArticleId><ArticleId IdType="pubmed">29459780</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuana Y, et al. Handling and storage of human body fluids for analysis of extracellular vesicles. J. Extracell. Vesicles. 2015;4:29260. doi: 10.3402/jev.v4.29260.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/jev.v4.29260</ArticleId><ArticleId IdType="pmc">PMC4643195</ArticleId><ArticleId IdType="pubmed">26563735</ArticleId></ArticleIdList></Reference><Reference><Citation>Manek R, et al. Protein Biomarkers and Neuroproteomics Characterization of Microvesicles/Exosomes from Human Cerebrospinal Fluid Following Traumatic Brain Injury. Mol. Neurobiol. 2018;55:6112&#x2013;6128. doi: 10.1007/s12035-017-0821-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0821-y</ArticleId><ArticleId IdType="pmc">PMC6359938</ArticleId><ArticleId IdType="pubmed">29188495</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuendl A, et al. Induction of alpha-synuclein aggregate formation by CSF exosomes from patients with Parkinson&#x2019;s disease and dementia with Lewy bodies. Brain. 2016;139:481&#x2013;494. doi: 10.1093/brain/awv346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv346</ArticleId><ArticleId IdType="pmc">PMC4805087</ArticleId><ArticleId IdType="pubmed">26647156</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiasserini D, et al. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. J. Proteom. 2014;106:191&#x2013;204. doi: 10.1016/j.jprot.2014.04.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jprot.2014.04.028</ArticleId><ArticleId IdType="pubmed">24769233</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, et al. UFLC-Derived CSF Extracellular Vesicle Origin and Proteome. Proteomics. 2018;18:e1800257. doi: 10.1002/pmic.201800257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201800257</ArticleId><ArticleId IdType="pubmed">30411858</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J. Glycoconjugates from extracellular vesicles: Structures, functions and emerging potential as cancer biomarkers. Biochim. Biophys. Acta Rev. Cancer. 2017;1868:157&#x2013;166. doi: 10.1016/j.bbcan.2017.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2017.03.007</ArticleId><ArticleId IdType="pubmed">28347750</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobelli S, Arno E, D&#x2019;Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 1986;46:3005&#x2013;3010.</Citation><ArticleIdList><ArticleId IdType="pubmed">3516389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ijsselstijn L, et al. Serum proteomics in amnestic mild cognitive impairment. Proteomics. 2013;13:2526&#x2013;2533. doi: 10.1002/pmic.201200190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201200190</ArticleId><ArticleId IdType="pubmed">23868823</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ostilio N, Sabatino G, Natoli C, Ullrich A, Iacobelli S. 90K (Mac-2 BP) in human milk. Clin. Exp. Immunol. 1996;104:543&#x2013;546. doi: 10.1046/j.1365-2249.1996.40745.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1996.40745.x</ArticleId><ArticleId IdType="pmc">PMC2200461</ArticleId><ArticleId IdType="pubmed">9099942</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoonsari PE, et al. Systematic analysis of the cerebrospinal fluid proteome of fibromyalgia patients. J. Proteom. 2019;190:35&#x2013;43. doi: 10.1016/j.jprot.2018.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jprot.2018.04.014</ArticleId><ArticleId IdType="pubmed">29656018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecube A, et al. Proteomic analysis of cerebrospinal fluid from obese women with idiopathic intracranial hypertension: a new approach for identifying new candidates in the pathogenesis of obesity. J. Neuroendocrinol. 2012;24:944&#x2013;952. doi: 10.1111/j.1365-2826.2012.02288.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2826.2012.02288.x</ArticleId><ArticleId IdType="pubmed">22296024</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen CT, Ostergaard O, Rasmussen NS, Jacobsen S, Heegaard NHH. A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus. Clin. Proteom. 2017;14:11. doi: 10.1186/s12014-017-9146-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12014-017-9146-0</ArticleId><ArticleId IdType="pmc">PMC5385087</ArticleId><ArticleId IdType="pubmed">28405179</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, et al. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. Sci. Rep. 2017;7:14352. doi: 10.1038/s41598-017-14747-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14747-5</ArticleId><ArticleId IdType="pmc">PMC5662597</ArticleId><ArticleId IdType="pubmed">29085039</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, et al. The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J. Neurol. Neurosurg. Psychiatry. 2017;88:557&#x2013;563. doi: 10.1136/jnnp-2016-314495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-314495</ArticleId><ArticleId IdType="pubmed">28285264</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, de Carvalho M. Emerging molecular biomarker targets for amyotrophic lateral sclerosis. Clin. Chim. Acta. 2016;455:7&#x2013;14. doi: 10.1016/j.cca.2016.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2016.01.011</ArticleId><ArticleId IdType="pubmed">26774696</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra H, et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol. 2012;10:e1001450. doi: 10.1371/journal.pbio.1001450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1001450</ArticleId><ArticleId IdType="pmc">PMC3525526</ArticleId><ArticleId IdType="pubmed">23271954</ArticleId></ArticleIdList></Reference><Reference><Citation>Strekalova H, et al. Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes. Neurobiol. Aging. 2006;27:1&#x2013;9. doi: 10.1016/j.neurobiolaging.2004.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.11.013</ArticleId><ArticleId IdType="pubmed">16298234</ArticleId></ArticleIdList></Reference><Reference><Citation>Escrevente C, et al. Functional role of N-glycosylation from ADAM10 in processing, localization and activity of the enzyme. Biochim. Biophys. Acta. 2008;1780:905&#x2013;913. doi: 10.1016/j.bbagen.2008.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2008.03.004</ArticleId><ArticleId IdType="pubmed">18381078</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoeck A, et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem. J. 2006;393:609&#x2013;618. doi: 10.1042/BJ20051013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20051013</ArticleId><ArticleId IdType="pmc">PMC1360713</ArticleId><ArticleId IdType="pubmed">16229685</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M, et al. Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson&#x2019;s disease. Acta Neuropathol. 2014;128:639&#x2013;650. doi: 10.1007/s00401-014-1314-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1314-y</ArticleId><ArticleId IdType="pmc">PMC4201967</ArticleId><ArticleId IdType="pubmed">24997849</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouveia RM, Gomes CM, Sousa M, Alves PM, Costa J. Kinetic analysis of L1 homophilic interaction: role of the first four immunoglobulin domains and implications on binding mechanism. J. Biol. Chem. 2008;283:28038&#x2013;28047. doi: 10.1074/jbc.M804991200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M804991200</ArticleId><ArticleId IdType="pmc">PMC2661381</ArticleId><ArticleId IdType="pubmed">18701456</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson, E. J. Proteins of the cerebrospinal fluid. Second edn, (Elsevier Academic Press, 2005).</Citation></Reference><Reference><Citation>Garranzo-Asensio M, et al. Identification of prefrontal cortex protein alterations in Alzheimer&#x2019;s disease. Oncotarget. 2018;9:10847&#x2013;10867. doi: 10.18632/oncotarget.24303.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.24303</ArticleId><ArticleId IdType="pmc">PMC5834268</ArticleId><ArticleId IdType="pubmed">29541381</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen M, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. doi: 10.1126/science.1260419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1260419</ArticleId><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Stampolidis P, Ullrich A, Iacobelli S. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention. Oncogene. 2015;34:39&#x2013;52. doi: 10.1038/onc.2013.548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2013.548</ArticleId><ArticleId IdType="pubmed">24362527</ArticleId></ArticleIdList></Reference><Reference><Citation>Laubli H, et al. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. J. Biol. Chem. 2014;289:33481&#x2013;33491. doi: 10.1074/jbc.M114.593129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.593129</ArticleId><ArticleId IdType="pmc">PMC4246102</ArticleId><ArticleId IdType="pubmed">25320078</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G, et al. Inducible LGALS3BP/90K activates antiviral innate immune responses by targeting TRAF6 and TRAF3 complex. PLoS Pathog. 2019;15:e1008002. doi: 10.1371/journal.ppat.1008002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008002</ArticleId><ArticleId IdType="pmc">PMC6705879</ArticleId><ArticleId IdType="pubmed">31404116</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu L, et al. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol. Syst. Biol. 2019;15:e8793. doi: 10.15252/msb.20188793.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/msb.20188793</ArticleId><ArticleId IdType="pmc">PMC6396370</ArticleId><ArticleId IdType="pubmed">30824564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono M, et al. Increased levels of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in idiopathic pulmonary fibrosis. Respir. Med. 2016;115:46&#x2013;52. doi: 10.1016/j.rmed.2016.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2016.04.013</ArticleId><ArticleId IdType="pubmed">27215503</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, et al. Exploring Cerebrospinal Fluid IgG N-Glycosylation as Potential Biomarker for Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2019;56:5729&#x2013;5739. doi: 10.1007/s12035-019-1482-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1482-9</ArticleId><ArticleId IdType="pubmed">30674035</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron, D El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph. Lateral Scler. Frontotemporal Degener. 2016;17:414&#x2013;425. doi: 10.3109/21678421.2016.1140786.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1140786</ArticleId><ArticleId IdType="pmc">PMC4950444</ArticleId><ArticleId IdType="pubmed">26864085</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves M, et al. Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis. Clin. Chim. Acta. 2015;438:342&#x2013;349. doi: 10.1016/j.cca.2014.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2014.09.011</ArticleId><ArticleId IdType="pubmed">25261856</ArticleId></ArticleIdList></Reference><Reference><Citation>Bovdilova A, et al. Posttranslational Modification of the NADP-Malic Enzyme Involved in C4 Photosynthesis Modulates the Enzymatic Activity during the Day. Plant. Cell. 2019;31:2525&#x2013;2539. doi: 10.1105/tpc.19.00406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1105/tpc.19.00406</ArticleId><ArticleId IdType="pmc">PMC6790091</ArticleId><ArticleId IdType="pubmed">31363039</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>